Benzene Ring In The Acid Moiety Patents (Class 554/218)
  • Patent number: 10111847
    Abstract: Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that fmd use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions fmd use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 30, 2018
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Michael S. Conte, Charles N. Serhan, Tejal A. Desai
  • Patent number: 9463177
    Abstract: Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that find use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions find use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: October 11, 2016
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Michael S. Conte, Charles N. Serhan, Tejal A. Desai
  • Publication number: 20150126759
    Abstract: Hydroxytyrosol derivative compositions, methods for their manufacture, and their use in personal care products are disclosed. Lipophilic hydroxytyrosol carbonate ester compound can be made by oxidizing a substituted hydroxybenzaldehyde compound with an oxidizing agent such as hydrogen peroxide under mild conditions. The process involves enzymatic esterification of 4-(2-hydroxyethyl)phenol to form the corresponding ester, the introduction of a formyl group ortho to the phenolic hydroxyl group of the ester to form a lipophilic formyltyrosol ester; oxidation of the lipophilic formyltyrosol ester with a peroxide compound to form a lipophilic hydroxytyrosol ester compound; and reaction of lipophilic hydroxytyrosol ester compound with carbonic acid ester derivatives to form a lipophilic hydroxytyrosol carbonic ester compound. These compounds are useful is a wide variety of personal care compositions as anti-aging compounds that are stable against oxidation.
    Type: Application
    Filed: November 4, 2013
    Publication date: May 7, 2015
    Applicant: Eastman Chemical Company
    Inventors: Neil Warren Boaz, Robert Joseph Maleski
  • Publication number: 20150073047
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Application
    Filed: August 1, 2014
    Publication date: March 12, 2015
    Inventor: Nicos A. Petasis
  • Publication number: 20140323457
    Abstract: The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Inventors: Thomas Böttcher, Vadim Korotkov, Katrin Lorenz-Baath, Oliver Baron, Stephan Sieber
  • Publication number: 20140275247
    Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: A.T. Resolve Sarl
    Inventors: Per Gjorstrup, C. Eric Schwartz
  • Patent number: 8802874
    Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: August 12, 2014
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Patent number: 8802881
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: August 12, 2014
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Publication number: 20140179630
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Application
    Filed: October 28, 2013
    Publication date: June 26, 2014
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. SERHAN, Bruce D. LEVY
  • Patent number: 8604229
    Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond the oral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: December 10, 2013
    Assignees: University of Southern California, Trustees of Boston University, Brigham and Women's Hospital, Inc.
    Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
  • Publication number: 20130225681
    Abstract: Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R?C(0); —OC(O)— or —CH(OH)—; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A and B form a 5-7 membered cycloalkyl substituted with COOFt W=0, S or NFt Y=0,S,NH or CH2; m=0-2; p=1-7; have been prepared. These compounds and their pharmaceutically acceptable salts have beneficial therapeutic effects to prevent or treat a condition related to (l) blood disorders, (ii) inflammation related diseases, (iii) renal disorders and/or renal disorders complications, or (iv) fibrosis-related organ dysfunction.
    Type: Application
    Filed: October 26, 2011
    Publication date: August 29, 2013
    Applicant: PROMETIC BIOSCIENCES INC.
    Inventors: Boulos Zacharie, Christopher Penney, Shaun Abbott, Lyne Gagnon, Brigette Grouix, Pierre Laurin
  • Publication number: 20120264713
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Application
    Filed: January 15, 2011
    Publication date: October 18, 2012
    Inventors: Charles N. Serhan, Bruce D. Levy
  • Publication number: 20120142772
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Application
    Filed: February 13, 2012
    Publication date: June 7, 2012
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventor: Nicos A. PETASIS
  • Publication number: 20120114566
    Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 10, 2012
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, UNIVERSITY OF SOUTHERN CALIFORNIA, BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
  • Publication number: 20120100073
    Abstract: Fatty acid analogue (FAA) molecules comprising positron-emitting radionuclides, salts thereof, and FAA-triglycerides are disclosed. Also disclosed are methods of synthesis, and methods of imaging distribution and metabolism of fatty acids and fatty acid triglycerides.
    Type: Application
    Filed: May 4, 2010
    Publication date: April 26, 2012
    Applicant: WASHINGTON UNIVERSITY
    Inventors: Robert H. Mach, Robert John Gropler, Zhude Tu, Pilar Herrero
  • Patent number: 8115023
    Abstract: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: February 14, 2012
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Patent number: 8093417
    Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: January 10, 2012
    Assignees: Trustees of Boston University, Brigham and Women's Hospital, Inc., University of Southern California
    Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
  • Publication number: 20110064677
    Abstract: This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.
    Type: Application
    Filed: September 28, 2010
    Publication date: March 17, 2011
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BRIGHAM AND WOMEN'S HOSPITAL, INC., UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Thomas E. Van Dyke, Nicos A. Petasis, Charles N. Serhan
  • Patent number: 7534817
    Abstract: This invention provides sarganol bis-succinate and alkyl and aryl derivatives thereof as potent apoptogens (antineoplastic agents) with high selectivity for cancer cells.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: May 19, 2009
    Inventor: Edward C. Leonard
  • Publication number: 20080182901
    Abstract: This invention is directed to a crystalline acid of a lipoxin A4 analog of Formula (II): wherein: R1 is —O—, —S(O)t— (where t is 0, 1 or 2), or a straight or branched alkylene chain; and R2 is aryl (optionally substituted by one or more substituents selected from alkyl, alkoxy, halo, haloalkyl and haloalkoxy) or aralkyl (optionally substituted by one or more substituents selected from f alkyl, alkoxy, halo, haloalkyl and haloalkoxy); and wherein the compound of Formula (II) is a single stereoisomer or any mixture of stereoisomers. This crystalline acid is useful in treating disease-states characterized by inflammation, such as inflammatory and autoimmune disorders or pulmonary or respiratory tract inflammations in humans. Methods of preparing the crystalline acid are also described.
    Type: Application
    Filed: December 3, 2007
    Publication date: July 31, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Klaus Bartel, Danja Grossbach, William J. Guilford, Michael Sander, Gabriele Winter
  • Patent number: 7294728
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Grant
    Filed: September 8, 2005
    Date of Patent: November 13, 2007
    Inventor: Charles N. Serhan
  • Patent number: 7223877
    Abstract: This invention provides novel antioxidants comprising hydroquinone substituted polyunsaturated fatty acids. Such fatty acids can be obtained from crude kombo butter and are suitable for preventing oxidation of various organic materials. In particular, the invention relates to the use of these fatty acids as antioxidants in the treatment of cancer, the inhibition of proliferation of cells, in lowering levels of cholesterol both in vivo and in vitro and in the treatment of cognitive disorders, including but not limited to Alzheimer's disease.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: May 29, 2007
    Inventor: Edward C. Leonard
  • Publication number: 20040162347
    Abstract: This invention provides novel antioxidants comprising hydroquinone substituted polyunsaturated fatty acids. Such fatty acids can be obtained from crude kombo butter and are suitable for preventing oxidation of various organic materials. In particular, the invention relates to the use of these fatty acids as antioxidants in the treatment of cancer, the inhibition of proliferation of cells, in lowering levels of cholesterol both in vivo and in vitro and in the treatment of cognitive disorders, including but not limited to Alzheimer's disease.
    Type: Application
    Filed: February 17, 2004
    Publication date: August 19, 2004
    Inventor: Edward C. Leonard
  • Patent number: 6713512
    Abstract: This invention provides a novel antioxidant, kombic acid or a derivative thereof, obtained from crude kombo butter suitable for preventing oxidation of various organic materials. In particular, the invention relates to the use of kombic acid as an antioxidant in the treatment of cancer, the inhibition of proliferation of cells, and in lowering levels of cholesterol both in vivo and in vitro.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: March 30, 2004
    Inventor: Edward C. Leonard
  • Patent number: 6653493
    Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: November 25, 2003
    Assignee: The Brigham and Women's Hospital
    Inventor: Charles N. Serhan
  • Patent number: 6441036
    Abstract: The present invention relates to novel fatty acid analogous of the general forumla I: CH3—[CH2]m—[xi—CH2]n—COOR, as defined in the specification, which can be used for the treatment and/or prevention of obesity, fatty liver and hypertension. Further, the invention relates to a nutritional composition comprising such fatty acid analogues, and a method for reducing the total weight, or the amount of adipose tissue in an animal. The invention also relates to a method for improving the quality of product such as meat, milk and eggs.
    Type: Grant
    Filed: January 27, 2001
    Date of Patent: August 27, 2002
    Assignee: Thia Medica AS
    Inventor: Rolf Berge
  • Patent number: 6326397
    Abstract: The present invention relates to novel retinoid antagonists of the formula I wherein the dotted bond can be either hydrogenated or form a double bond; and, when the dotted bond forms a double bond, R1 is lower alkyl and R2 is hydrogen; and, when the dotted bond is hydrogenated, R1 and R2 taken together are methylene to form a cis-substituted cyclopropyl ring; R3 is hydroxy or lower alkoxy; R4 is alkyl or alkoxy; and R5 and R6 are, independently, a C4-12 alkyl or a 5-12 cycloalkyl substituent containing from 1-3 rings which are either unsubstituted or substituted with from 1-3 lower alkyl groups, with the carbon atom of R5 and R6 being linked to the remainder of the molecule to form a quaternary carbon atom pharmaceutically acceptable salts of carbocylic acids of the formula I; as well as method for the treatment of osteoporosis and preneoplastic and neoplastic diseases, and a method for reducing or abolishing adverse events in subjects receiving retinoid agonist treatment by administering a
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: December 4, 2001
    Assignee: Hoffman-La Roche Inc.
    Inventors: Werner Bollag, Michael Klaus, Peter Mohr, Paola Panina-Bordignon, Michael Rosenberger, Francesco Sinigaglia
  • Patent number: 6326499
    Abstract: Omega chain modified 15-HETE derivatives and methods of their use for treating dry eye are disclosed.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: December 4, 2001
    Assignee: Alcon Universal Ltd.
    Inventor: David B. Belanger
  • Patent number: 6313088
    Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: February 7, 1997
    Date of Patent: November 6, 2001
    Assignee: Emisphere Technologies, Inc.
    Inventors: Andrea Leone-Bay, Eric Wang, Donald J. Sarubbi, Harry Leipold, Nai Fang Wang
  • Patent number: 6201144
    Abstract: Fatty ether compounds and a process for their production is disclosed. The compounds possess low viscosity and low temperature melting point properties and may be used as viscosity modifiers in the creation of cosmetics and complete vegetable oil based biodegradable fluids such as hydraulic fluids and dielectric fluids. Formation of these fatty ether compounds is by reaction of the appropriate hydroxy fatty acid or lactone with a nucleophilic alcohol in the presence of an acid catalyst to produce fatty ether esters. Following their formation, the fatty ether esters may be recovered for subsequent use, or in the alternative, they may either be hydrolyzed to produce fatty ether acids or transesterified with a different nucleophilic alcohol in the presence of an acid catalyst to produce alternate ester variants.
    Type: Grant
    Filed: May 29, 1996
    Date of Patent: March 13, 2001
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Terry A. Isbell, Melissa S. Mund
  • Patent number: 6083984
    Abstract: Two new forms of prodrug for phenylacetate, of even congeners of phenylalkanoic acid and phenylalkenoic acids, which are the phenylalkanoic or phenylalkenoic esters of glycerol, or the ethyl esters of phenylalkanoic acid or phenylalkenoic acids. These forms of the drugs provide a convenient dosage form of the drugs. The prodrugs of the invention are useful to treat patients with diseases of nitrogen accumulation, patients with certain .beta.-hemoglobinopathies, anemia, and cancer.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: July 4, 2000
    Assignee: Brusilow Enterprises LLC
    Inventor: Saul W. Brusilow
  • Patent number: 6005125
    Abstract: A universal linker for solid-phase nucleic acid synthesis that is cleaved under conditions orthogonal to those used during the synthesis and deprotection of nucleic acids such as dsDNA or RNA fragments is disclosed. The invention includes compounds of the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of OH, OR.sub.2 and an amino functionalized support and n is an integer ranging from about 1 to about 1000 or more preferably from about 1 to about 100 or greater and R.sub.2 is an alkyl (C.sub.1-20) or greater.
    Type: Grant
    Filed: May 6, 1997
    Date of Patent: December 21, 1999
    Assignee: Rutgers the State University of New Jersey
    Inventors: Xiaohu Zhang, Roger A. Jones
  • Patent number: 5998642
    Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis, structure and/or function of the glycosyl phosphatidylinositol (GPI) anchor of said parasite may be affected by incorporating into said GPI anchor selected analogs of myristic acid containing various heteroatoms, substituents and unsaturated bonds, including ester-containing analogs, ketocarbonyl-containing analogs, sulfur-containing analogs, double bond- and triple bond-containing analogs, aromatic moiety-containing analogs, nitrated analogs and halogenated analogs.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: December 7, 1999
    Assignee: Washington University
    Inventors: Jeffrey I. Gordon, George W. Gokel, Paul T. Englund
  • Patent number: 5968979
    Abstract: Two new forms of prodrug for phenylacetate, of even congeners of phenylalkanoic acid and phenylalkenoic acids, which are the phenylalkanoic or phenylalkenoic esters of glycerol, or the ethyl esters of phenylalkanoic acid or phenylalkenoic acids. These forms of the drugs provide a convenient dosage form of the drugs. The prodrugs of the invention are useful to treat patients with diseases of nitrogen accumulation, patients with certain .beta.-hemoglobinopathies, anemia, and cancer.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: October 19, 1999
    Assignee: Brusilow Enterprises LLC
    Inventor: Saul W. Brusilow
  • Patent number: 5654452
    Abstract: Aromatic acid-derived lipophilic polyhalogenated compounds are provided for use as contrast agents in diagnostic imaging or as therapeutic agents. These compounds are particularly useful when incorporated into an oil-in-water emulsion for tissue-specific delivery to the liver. For hepatocyte-selective delivery, the emulsion is chylomicron remnant-like by being in a size range of 50 to 200 nm and having a composition simulating naturally-occuring chylomicron remnants.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 5, 1997
    Assignee: Molecular Biosystems, Inc.
    Inventors: Rolf Lohrmann, Dung K. Hong
  • Patent number: 5453525
    Abstract: Perhydro-5,5-8a-trimethyl-2-naphthalenone is prepared by acid cyclization of carboxylic esters of formula ##STR1## having a double bond in one of the positions indicated by the dotted lines and wherein symbol R designates a C.sub.1 -C.sub.6 alkyl radical, X stands for a monovalent radical of formula P(O)(OR.sup.1).sub.2 or C(O)R.sup.2, R.sup.1 represents a C.sub.1 -C.sub.6 alkyl group and R.sup.2 is either a linear or branched alkyl group or a substituted or unsubstituted phenyl radical, and wherein the wavy line represents a C--C bond of cis or trans configuration, or of formula ##STR2## wherein the wavy lines and symbol R are defined as above, and R.sup.0 represents a C.sub.3 -C.sub.6 alkyl radical, preferably branched, followed by basic decarboxylation of the obtained product.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: September 26, 1995
    Assignee: Firmenich SA
    Inventors: Roger L. Snowden, Cyril Mahaim, Dana P. Simmons
  • Patent number: 5410078
    Abstract: An unsaturated acid-functional monomer having the structure: ##STR1## wherein R.sup.1 is hydrogen or methyl and Z is nothing or is a divalent radical of 1 to about 20 carbons.
    Type: Grant
    Filed: January 3, 1994
    Date of Patent: April 25, 1995
    Assignee: The Sherwin-Williams Company
    Inventor: Rodney M. Harris
  • Patent number: 5369126
    Abstract: A compound of the formula ##STR1## its pharmaceutically acceptable salts, and its pharmaceutically acceptable hydrolyzable esters for reducing sebum secretion and combatting acne as well as oral and topical compositions for use thereof.
    Type: Grant
    Filed: January 6, 1993
    Date of Patent: November 29, 1994
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas I. Doran, Michael Rosenberger, Stanley S. Shapiro
  • Patent number: 5364948
    Abstract: This invention relates to compounds of structural formula (I) isolated from an aerobic fermentation of Trichoderma viride MF5628, ATCC 74084: ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents. These compounds are also potent antifungal agents. Additionally, they inhibit farnesyl protein transferase and farnesylation of the oncogene protein Ras and are thus useful in treating cancer. This invention also relates to a process for obtaining compounds of structural formula (I).
    Type: Grant
    Filed: February 9, 1993
    Date of Patent: November 15, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Guy H. Harris, Deborah Zink, E. Tracy T. Jones, Yu L. Kong
  • Patent number: 5279759
    Abstract: Alpha-(p-alkoxybenzylidene) carboxylic acids are used as color stabilizers, processing aids and whiteners for soap.
    Type: Grant
    Filed: December 9, 1992
    Date of Patent: January 18, 1994
    Assignee: Henkel Corporation
    Inventors: Louis Rebrovic, Alan C. Kilbarger
  • Patent number: 5266713
    Abstract: Aryl alkenoic acid derivatives, and physiologically acceptable salts thereof, are provided which are potent leukotriene antagonists and may be used for the treatment of circulatory diseases and preferably for respiratory diseases such as asthma. The derivatives have a general formula I ##STR1## in which X is --S--,W is CH.dbd.CH;o is 1 to 4;n is 2 to 6;m is 0 to 2;T and Z, same or different, represent oxygen or a direct bond;R.sup.2 and R.sup.3, represent hydrogen, or fluorine;A represents carboxyl, CO.sub.2 R.sub.4.sup.4, wherein R.sup.4 is lower alkylR is ##STR2## wherein Y represents carboxyl, CO.sub.2 R.sup.4, wherein R.sup.4 is lower alkylR.sup.7 and R.sup.8, same or different, represent H or lower alkyl;R.sup.9 represents --OH, --O-alkyl, NH.sub.2 or a NHCH.sub.2 CO.sub.2 H group; andR.sup.10 R3 is H.
    Type: Grant
    Filed: August 12, 1992
    Date of Patent: November 30, 1993
    Assignee: Miles Inc.
    Inventors: Trevor S. Abram, Peter Norman, Stephen R. Tudhope, Harold C. Kluender, Robert N. Schut, Heinrich Meier, Ulrich Rosentreter
  • Patent number: 5219479
    Abstract: Compounds of general formula (I), wherein R.sup.1 is hydrogen, C.sub.1-4 alkyl or a group of formula (II): --O(CH(R.sup.10)CH.sub.2 O).sub.n R.sup.20, R.sup.2 is hydrogen or a group of formula (III): --O(CH(R.sup.11)CH.sub.2 O).sub.m R.sup.21, R.sup.3 is a group of formula (IV): --(CH(R.sup.12)CH.sub.2 O).sub.p R.sup.22, and R.sup.4 is a group of formula (V): --(CH(R.sup.13)CH.sub.2 O).sub.r R.sup.23, where R.sup.10, R.sup.11, R.sup.12 and R.sup.13 each is hydrogen or CH.sub.3, R.sup.20 R.sup.21, R.sup.22 and R.sup.23 each is an acyl moiety of a polycarboxylic acid, and n, m, p and r each is an integer from 1 to 15; q is 1 or 2; with the provisos that if q is 2, then the 2 groups R.sup.1 may be the same or different and the 2 groups R.sup.2 may be the same or different; and, if one or more of the groups R.sup.20, R.sup. 21, R.sup.22, and R.sup.23 is an acyl moiety of a polycarboxylic acid group, then 0-3 of the remaining carboxy groups of the polycarboxylic acid form the acyl function(s) of a moiety R.sup.
    Type: Grant
    Filed: May 21, 1991
    Date of Patent: June 15, 1993
    Assignee: Esti Chem A/S
    Inventors: Thomas Mathiesen, Jan W. Jensen
  • Patent number: 5218138
    Abstract: This invention is directed to a method for stereoselectively preparing a syn-dihydroxylated compound comprising reacting a 3-hydroxyket-1-one and a sterically hindered dialkylated borane to form a complex at about -50.degree. C. to about 0.degree. C., and reducing the complex with hydride at about -25.degree. C. to about 50.degree. C.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: June 8, 1993
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fang-Ting Chiu, William L. Studt
  • Patent number: 5166377
    Abstract: The invention concerns novel 4-phenyl-1,3-dioxan-5-ylalkenoic acid derivatives of the formula I having cis relative stereochemistry at positions 4 and 5 of the dioxane ring and wherein Ra and Rb are variously hydrogen, alkyl, halogenoalkyl, alkenyl, and optionally substituted aryl or arylalkyl, Rc is hydroxy, alkoxy or alkanesulphonamido, n is 1 or 2, A is ethylene or vinylene, Y is (2-5C)polymethylene optionally substituted by alkyl, and benzene ring B is optionally substituted phenyl, or, when Rc is hydroxy, a salt thereof. The acid derivatives antagonize one or more of the actions of thromboxane A.sub.2 (TXA.sub.2) and are expected to be of value in those disease conditions in which TXA.sub.2 is involved. The invention also provides pharmaceutical compositions containing an acid derivative of formula I, and processes for their chemical production.
    Type: Grant
    Filed: February 9, 1988
    Date of Patent: November 24, 1992
    Assignee: Imperial Chemical Industries PLC
    Inventors: Andrew G. Brewster, Peter W. R. Caulkett
  • Patent number: 5145611
    Abstract: Carboxylic acid derivatives of the formula ##STR1## R.sub.1 is alkoxy, alkylthio, alkylsulphinyl, alkulsulphonyl, alkylamino, cycloalkyl, or cycloalkoxy or optionally substituted aryl, aryloxy, arylthio, arylsulphinyl, arylsulphonyl or arylamino. R.sub.2 is optionally substituted aryl or, when B is alkylene also a hydrogen atom. A is a straight-chained or branched, saturated or unsaturated alkylene containing 3 to 10 carbon atoms which is optionally interrupted by a heteratom attached to a saturated carbon and has a chain length of at least 3 atoms. Y is S(O).sub.n group or oxygen, n being 0, 1 or 2. B is a valency bond or a straight-chained or branched, saturated or unsaturated alkylene containing 1 to 18 carbon atoms. Physiologically acceptable salts, esters and amides thereof are also included. The compounds are useful in the treatment of metabolic diseases.
    Type: Grant
    Filed: January 12, 1988
    Date of Patent: September 8, 1992
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hans P. Wolff, Ernst-Christian Witte, Hans-Frieder Kuehnle